Details of Disease

General Information of Disease (ID: DISC2BT9)

Disease Name	Ocular hypertension
Disease Class	9C61: Glaucoma
Definition	Abnormally high intraocular pressure.
Disease Hierarchy	DISB52BH: Eye disorder DISR4QMU: Increase blood pressure DISC2BT9: Ocular hypertension
ICD Code	ICD-11 ICD-11: 9C61.01 ICD-9 ICD-9: 365.04 Expand ICD-11 '9C61.01 Expand ICD-9 365.04
Disease Identifiers	MONDO ID MONDO_0006875 MESH ID D009798 UMLS CUI C0028840 MedGen ID 10423 SNOMED CT ID 4210003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 17 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Betaxolol	DM6EUL5	Approved	Small molecular drug	[1]
Bimatoprost	DMX0E5B	Approved	Small molecular drug	[2]
Brimonidine	DMQLT4N	Approved	Small molecular drug	[3]
Brinzolamide	DMBAPFG	Approved	Small molecular drug	[4]
Carteolol	DMFMDOB	Approved	Small molecular drug	[5]
Dorzolamide	DMA17D0	Approved	Small molecular drug	[6]
Latanoprost	DMI5OXG	Approved	Small molecular drug	[7]
Levobetaxolol	DMSREPX	Approved	Small molecular drug	[8]
Levobunolol	DMTNFCQ	Approved	Small molecular drug	[9]
Mannitol	DMSCDY9	Approved	Small molecular drug	[10]
Metipranolol	DMJMVKI	Approved	Small molecular drug	[11]
Paclitaxel	DMLB81S	Approved	Small molecular drug	[12]
Pilocarpine	DMV9ADG	Approved	Small molecular drug	[13]
Tafluprost	DMFC41K	Approved	Small molecular drug	[14]
Timolol	DM3NXRU	Approved	Small molecular drug	[15]
Travoprost	DM20K91	Approved	Small molecular drug	[16]
Unoprostone	DMXNR04	Approved	Small molecular drug	[17]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 Drug(s)

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AL-54478	DME6UTA	Phase 2	NA	[18]
AL-59412C	DMBV2KX	Phase 2	NA	[19]
AZD-4017	DML9M5S	Phase 2	Small molecular drug	[20]
MSH-1001	DMUM370	Phase 2	NA	[21]
Simenepag isopropyl	DMX1UHG	Phase 2	Small molecular drug	[22]
SYL-040012	DMXLE71	Phase 2	siRNA drug	[23]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SYL-040003	DM7YB08	Investigative	siRNA drug	[24]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 15 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
LINGO1	TTZYQ80	Limited	Biomarker	[25]
PTGER2	TT1ZAVI	Limited	Biomarker	[26]
PTGFR	TTT2ZAR	Limited	Biomarker	[27]
APOA1	TT5S8DR	moderate	Biomarker	[28]
BCL2L1	TTRE6AX	moderate	Biomarker	[29]
C1QB	TT8A9DM	moderate	Biomarker	[30]
C3	TTJGY7A	moderate	Biomarker	[30]
CRYAA	TT8CWJG	moderate	Biomarker	[28]
GLI1	TTJOMH6	moderate	Biomarker	[31]
SHH	TTIENCJ	moderate	Biomarker	[31]
SMO	TT8J1S3	moderate	Biomarker	[31]
CYP1B1	TTI84H7	Strong	Genetic Variation	[32]
GHSR	TTWDC17	Strong	Biomarker	[33]
MMP1	TTMX39J	Strong	Therapeutic	[34]
OPA1	TTTU49Q	Strong	Biomarker	[35]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 DTT(s)

This Disease Is Related to 17 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ALKBH1	OTADGU5D	Limited	Biomarker	[36]
DCLRE1B	OT2LFW7A	Limited	Biomarker	[37]
GPR158	OTYOC1RQ	Limited	Biomarker	[38]
GSDMD	OTH39BKI	Limited	Biomarker	[39]
HPSE2	OTGEPP8V	Limited	Genetic Variation	[40]
NANOS2	OTFM2IDJ	Limited	Biomarker	[41]
NEFH	OTMSCW5I	Limited	Biomarker	[42]
OPN4	OT1LZ7TS	Limited	Biomarker	[43]
PEX19	OTQIDE9Z	Limited	Genetic Variation	[44]
SPRR2A	OT62ZU6B	Limited	Genetic Variation	[45]
SRSF3	OTOFT707	Limited	Genetic Variation	[46]
TLX2	OTPFAUM8	Limited	Biomarker	[47]
ACSM3	OT0AE1IV	moderate	Biomarker	[48]
CRYBA1	OT8617WJ	moderate	Biomarker	[48]
TPI1	OT14KP4B	moderate	Biomarker	[28]
DDIT3	OTI8YKKE	Strong	Therapeutic	[49]
POU4F1	OTMHYGWQ	Strong	Biomarker	[50]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 DOT(s)

References

1	Betaxolol FDA Label
2	Bimatoprost FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 520).
4	Brinzolamide FDA Label
5	Carteolol FDA Label
6	Dorzolamide FDA Label
7	Latanoprost FDA Label
8	Levobetaxolol FDA Label
9	Levobunolol FDA Label
10	Mannitol FDA Label
11	Metipranolol FDA Label
12	Paclitaxel FDA Label
13	Pilocarpine FDA Label
14	Tafluprost FDA Label
15	Timolol FDA Label
16	Travoprost FDA Label
17	Unoprostone FDA Label
18	ClinicalTrials.gov (NCT01318252) AL-54478 Proof of Concept Study. U.S. National Institutes of Health.
19	ClinicalTrials.gov (NCT01312454) Safety and Intraocular Pressure (IOP) Lowering Effect of AL-59412C. U.S. National Institutes of Health.
20	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7695).
21	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023795)
22	Macrogol 15 hydroxystearate formulations US 20130005665 A1.
23	ClinicalTrials.gov (NCT02250612) SYL040012, Treatment for Open Angle Glaucoma. U.S. National Institutes of Health.
24	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2599).
25	Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma.Neuroscience. 2009 Aug 18;162(2):375-82. doi: 10.1016/j.neuroscience.2009.04.075. Epub 2009 May 5.
26	Activation of Prostaglandin FP and EP2 Receptors Differently Modulates Myofibroblast Transition in a Model of Adult Primary Human Trabecular Meshwork Cells.Invest Ophthalmol Vis Sci. 2016 Apr;57(4):1816-25. doi: 10.1167/iovs.15-17693.
27	Contribution of prostanoid FP receptor and prostaglandins in transient inflammatory ocular hypertension.Sci Rep. 2018 Jul 23;8(1):11098. doi: 10.1038/s41598-018-29273-1.
28	Proteomic analysis of rat retina in a steroid-induced ocular hypertension model: potential vulnerability to oxidative stress.Jpn J Ophthalmol. 2008 Mar-Apr;52(2):84-90. doi: 10.1007/s10384-007-0507-5. Epub 2008 Apr 30.
29	Alteration of retinal intrinsic survival signal and effect of alpha2-adrenergic receptor agonist in the retina of the chronic ocular hypertension rat.Vis Neurosci. 2007 Mar-Apr;24(2):127-39. doi: 10.1017/S0952523807070150.
30	Retinal synthesis and deposition of complement components induced by ocular hypertension.Exp Eye Res. 2006 Sep;83(3):620-8. doi: 10.1016/j.exer.2006.03.002. Epub 2006 May 4.
31	Neuroprotective effect of upregulated sonic Hedgehog in retinal ganglion cells following chronic ocular hypertension.Invest Ophthalmol Vis Sci. 2010 Jun;51(6):2986-92. doi: 10.1167/iovs.09-4151. Epub 2010 Jan 13.
32	Survey of familial glaucoma shows a high incidence of cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1) mutations in non-consanguineous congenital forms in a Spanish population.Mol Vis. 2013 Aug 4;19:1707-22. Print 2013.
33	Identification of the ghrelin-GHSR 1 system and its influence in the modulation of induced ocular hypertension in rabbit and rat eyes.Peptides. 2014 Jul;57:59-66. doi: 10.1016/j.peptides.2014.04.013. Epub 2014 Apr 26.
34	Treatment of sheep steroid-induced ocular hypertension with a glucocorticoid-inducible MMP1 gene therapy virus.Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3042-8. doi: 10.1167/iovs.09-4920. Epub 2010 Jan 20.
35	Corneal biomechanics and biomechanically corrected intraocular pressure in primary open-angle glaucoma, ocular hypertension and controls.Br J Ophthalmol. 2020 Jan;104(1):121-126. doi: 10.1136/bjophthalmol-2018-313493. Epub 2019 Mar 28.
36	Blood groups as genetic markers in glaucoma.Br J Ophthalmol. 1988 Apr;72(4):270-3. doi: 10.1136/bjo.72.4.270.
37	Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.Drugs. 2018 May;78(7):773-780. doi: 10.1007/s40265-018-0914-6.
38	GPR158, an orphan member of G protein-coupled receptor Family C: glucocorticoid-stimulated expression and novel nuclear role.PLoS One. 2013;8(2):e57843. doi: 10.1371/journal.pone.0057843. Epub 2013 Feb 25.
39	Inflammasome Activation Induces Pyroptosis in the Retina Exposed to Ocular Hypertension Injury.Front Mol Neurosci. 2019 Mar 13;12:36. doi: 10.3389/fnmol.2019.00036. eCollection 2019.
40	The atrial natriuretic peptide gene in patients with familial primary open-angle glaucoma.Biochem Biophys Res Commun. 1996 Jun 14;223(2):221-5. doi: 10.1006/bbrc.1996.0874.
41	Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage.Invest Ophthalmol Vis Sci. 2005 Apr;46(4):1313-21. doi: 10.1167/iovs.04-0829.
42	Involvement of microglia in early axoglial alterations of the optic nerve induced by experimental glaucoma.J Neurochem. 2017 Jul;142(2):323-337. doi: 10.1111/jnc.14070. Epub 2017 Jun 9.
43	Shared and Differential Retinal Responses against Optic Nerve Injury and Ocular Hypertension.Front Neurosci. 2017 Apr 26;11:235. doi: 10.3389/fnins.2017.00235. eCollection 2017.
44	Clinical spectrum of pseudoexfoliation syndrome-An electronic records audit.PLoS One. 2017 Oct 27;12(10):e0185373. doi: 10.1371/journal.pone.0185373. eCollection 2017.
45	Incidence and risk factors for post-penetrating keratoplasty glaucoma: A systematic review and meta-analysis.PLoS One. 2017 Apr 21;12(4):e0176261. doi: 10.1371/journal.pone.0176261. eCollection 2017.
46	Analysis of single nucleotide polymorphisms in the SFRS3 and FKBP4 genes in corticosteroid-induced ocular hypertension.Ophthalmic Genet. 2012 Dec;33(4):221-4. doi: 10.3109/13816810.2012.716488. Epub 2012 Aug 27.
47	Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma.Br J Pharmacol. 2019 Apr;176(8):1079-1089. doi: 10.1111/bph.14328. Epub 2018 May 24.
48	Retinal gene profiling in a hereditary rodent model of elevated intraocular pressure.Mol Vis. 2006 Oct 18;12:1199-210.
49	Ocular-specific ER stress reduction rescues glaucoma in murine glucocorticoid-induced glaucoma.J Clin Invest. 2014 May;124(5):1956-65. doi: 10.1172/JCI69774. Epub 2014 Apr 1.
50	Methyl 3,4-dihydroxybenzoate protects retina in a mouse model of acute ocular hypertension through multiple pathways.Exp Eye Res. 2019 Apr;181:15-24. doi: 10.1016/j.exer.2019.01.010. Epub 2019 Jan 10.